![Erman Akkus: Our study on SGLT2 and papillary RCC](https://oncodaily.com/pub/uploads/2025/01/Frame-348-1-e1727723256311.png-1-e1739106724758-1280x720.webp)
Erman Akkus/X
Feb 10, 2025, 15:21
Erman Akkus: Our study on SGLT2 and papillary RCC
Erman Akkus, Medical Oncology Fellow at Ankara University, shared an article on X:
“Our study on SGLT2 and papillary RCC has been published!
SGLT2 inhibitors dramatically changed the treatment of diabetes, heart failure and chronic kidney disease.
SGLT2 is selectively expressed in kidney.
Our study suggest SGLT2 may be a potential biomarker and target in papillary RCC, calling for further studies.”
Sodium-Glucose Cotransporter 2 (SGLT2) as a Potential Biomarker and Target in Papillary Renal Cell Carcinoma.
Authors: Erman Akkus, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 10, 2025, 15:21
Feb 10, 2025, 15:11
Feb 10, 2025, 14:47
Feb 10, 2025, 14:12
Feb 10, 2025, 11:18
Feb 10, 2025, 10:52